AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
ArriVent BioPharma, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG011N37VW3
21.00▲ 1.80 (9.38%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
19.20
Day's Range
18.18 – 21.23
52-Week Range
11.36 – 35.83
Volume
3.2M
Avg Volume
1.7M
Share Statistics
Shares Outstanding
Employees
77
Exchange
XNAS
Listed
2024-01-26
Share count as of August 10, 2026

ArriVent BioPharma, Inc. Common Stock (AVBP) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about ArriVent BioPharma, Inc. Common Stock (AVBP)
What is ArriVent BioPharma, Inc. Common Stock's Market Cap?
ArriVent BioPharma, Inc. Common Stock's Market Cap is $1.0B, based on as-reported figures from SEC (XBRL) filings.
What is ArriVent BioPharma, Inc. Common Stock's Enterprise Value?
ArriVent BioPharma, Inc. Common Stock's Enterprise Value is $662.3M, based on as-reported figures from SEC (XBRL) filings.
What is ArriVent BioPharma, Inc. Common Stock's Net Income (TTM)?
ArriVent BioPharma, Inc. Common Stock's Net Income (TTM) is -$163.7M, based on as-reported figures from SEC (XBRL) filings.
What is ArriVent BioPharma, Inc. Common Stock's Diluted EPS (TTM)?
ArriVent BioPharma, Inc. Common Stock's Diluted EPS (TTM) is -3.32, based on as-reported figures from SEC (XBRL) filings.
What is ArriVent BioPharma, Inc. Common Stock's Net Debt?
ArriVent BioPharma, Inc. Common Stock's Net Debt is -$373.1M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · AVBPAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023
Operating expenses:
Research and development
General and administrative
Total operating expenses
Operating loss
Interest and investment income
Net loss
Net loss per share attributable to common stockholders, basic (in dollars per share)
Net loss per share attributable to common stockholders, diluted (in dollars per share)